{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["glofitamab","venetoclax","obinutuzumab"],["glofitamab","venetoclax","zanubrutinib","obinutuzumab"]],"indication":"high-risk mantle-cell lymphoma","name":"GLOASIS","nct_id":"NCT06558604","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=gloasis-nct06558604. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"GLOASIS","arms":[{"description":"* Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2\n* Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min)\n* Zanubrutinib PO 320 mg total daily dose (QD) From C1D2 continuously until end C35\n* Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35","label":"Cohort A - POD24","type":"EXPERIMENTAL"},{"description":"* Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2\n* Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min)\n* Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35","label":"Cohort B - BTKI failure","type":"EXPERIMENTAL"},{"description":"* Obinutuzumab IV infusion 2000 mg flat dose at C1D1 or Splited in 2 doses of 1000 mg at C1D1 and C1D2\n* Glofitamab IV infusion 2.5 mg C1D8 10 mg C1D15 30 mg C2D1 and C3D1 (infusion during min 4 hours ) 30 mg Each D1 for C4 to C6 (Infusion during min 2 hours ) 30 mg Each D1 for C7 to C12 (Infusion during min 90 min)\n* Zanubrutinib PO 320 mg total daily dose (QD) From C1D2 continuously until end C35\n* Venetoclax PO 20 mg/d C2D3 to C2D7 50 mg/d C2D8 to C2D14 100 mg/d C2D15 to C2D21 200 mg/d C3D1 to C3D7 400 mg/d From C3D8 continuously until end C35","label":"Cohort C - first Line","type":"EXPERIMENTAL"}],"collaborators":["BeiGene","Hoffmann-La Roche"],"completion_date":{"date":"2032-03","type":"ESTIMATED"},"conditions":["Lymphoma, Mantle-Cell"],"enrollment":{"count":100,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Obinutuzumab","otherNames":["Gazyvaro"],"type":"DRUG"},{"name":"Glofitamab","otherNames":["Columvi 10 mg"],"type":"DRUG"},{"name":"Venetoclax Oral Product","otherNames":["Venclyxto"],"type":"DRUG"},{"name":"Zanubrutinib Oral Capsule","otherNames":["Zanubrutinib (BGB-3111)"],"type":"DRUG"}],"last_update":"2026-07-10","lead_sponsor":"The Lymphoma Academic Research Organisation","official_title":"A Phase II, Multicenter, Open-label Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PFS at the end of C17 (each cycle is 21 days)","timeFrame":"end of cycle 17 (each cycle is 21 days)"}],"references":[],"start_date":{"date":"2025-02-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT06558604"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/gloasis-nct06558604"}